The document “Application for Quotation of +Securities” was lodged with ASX on 17 June, 2021.
Please click to review the full announcement at ASX.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)